Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Earnings Data
Report Date
Nov 05, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.69Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Zevra demonstrated strong financial performance with significant revenue growth from MIPLYFFA and strategic financial maneuvers, including the sale of PRV. The expansion efforts in Europe and increased coverage and retention rates for MIPLYFFA indicate positive momentum. However, challenges remain with the slow adoption of OLPRUVA and increased SG&A expenses. The limited progress in the DiSCOVER trial enrollment also poses a concern. Overall, the positive aspects outweigh the negatives, but challenges still need to be addressed.Company Guidance
Strong Financial Performance in Q2 2025
Net revenue reached $25.9 million, with a 26% increase in MIPLYFFA net revenue quarter-over-quarter, reflecting robust demand for the product.
Strategic Sale of PRV
Completed the sale of PRV for $150 million, which significantly strengthened Zevra's balance sheet.
U.S. Launch Success of MIPLYFFA
Achieved notable success with 129 prescription enrollment forms for MIPLYFFA and reached over a third of diagnosed Niemann-Pick Disease Type C (NPC) patients in the U.S.
European Expansion for Arimoclomol
Submitted a marketing authorization application for arimoclomol in Europe, marking a significant milestone in geographic expansion efforts.
Increased Coverage and Retention for MIPLYFFA
Achieved 52% coverage for MIPLYFFA and demonstrated strong retention rates among patients.
Strong Cash Position
Total cash, cash equivalents, and investments reached $217.7 million as of June 30, 2025, compared to $68.7 million at the end of the prior quarter.
ZVRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZVRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 12, 2025 | $11.76 | $9.43 | -19.81% |
May 13, 2025 | $7.87 | $8.14 | +3.43% |
Mar 11, 2025 | $8.07 | $7.92 | -1.86% |
Nov 12, 2024 | $8.57 | $8.66 | +1.05% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zevra Therapeutics (ZVRA) report earnings?
Zevra Therapeutics (ZVRA) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).
What is Zevra Therapeutics (ZVRA) earnings time?
Zevra Therapeutics (ZVRA) earnings time is at Nov 05, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZVRA EPS forecast?
ZVRA EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.